Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Gastric Cancer
Published in: Gastric Cancer 1/2009

01-04-2009 | Original Article

Impact of plasma tissue inhibitor of metalloproteinase-1 on long-term survival in patients with gastric cancer

Authors: Takaki Yoshikawa, Haruhiko Cho, Akira Tsuburaya, Osamu Kobayashi

Published in: Gastric Cancer | Issue 1/2009

Login to get access
Metadata
Title
Impact of plasma tissue inhibitor of metalloproteinase-1 on long-term survival in patients with gastric cancer
Authors
Takaki Yoshikawa
Haruhiko Cho
Akira Tsuburaya
Osamu Kobayashi
Publication date
01-04-2009
Publisher
Springer Japan
Published in
Gastric Cancer / Issue 1/2009
Print ISSN: 1436-3291
Electronic ISSN: 1436-3305
DOI
https://doi.org/10.1007/s10120-008-0494-3

Other articles of this Issue 1/2009

Gastric Cancer 1/2009 Go to the issue

Letter to the Editor

A comparison of gastric cancer between Japan and China

From the New Editors-in-Chief

Joint international efforts to combat a still-deadly disease: the next generation

From the New Editors-in-Chief

Toward a new level of international exchange of information about gastric cancer research: a message from a new editor-in-chief

Letter to the Editor

Modified Billroth-I reconstruction after distal gastrectomy

Erratum

Erratum: Ludwik Rydygier — contributor to modern surgery

Original Article

Expression of tight-junction-associated proteins in human gastric cancer: downregulation of claudin-4 correlates with tumor aggressiveness and survival
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits